{"nctId":"NCT00029536","briefTitle":"Progesterone vs Placebo Therapy for Women With Epilepsy","startDateStruct":{"date":"2000-10"},"conditions":["Epilepsy"],"count":294,"armGroups":[{"label":"Catamenial Epilepsy: Progesterone Lozenges","type":"EXPERIMENTAL","interventionNames":["Biological: Progesterone Lozenges"]},{"label":"Catamenial Epilepsy: Placebo Lozenges","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Matched Placebo Lozenges"]},{"label":"Noncatamenial Epilespy:Progesterone Lozenges","type":"EXPERIMENTAL","interventionNames":["Biological: Progesterone Lozenges"]},{"label":"Noncatamenial Epilespy: Placebo Lozenges","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Matched Placebo Lozenges"]}],"interventions":[{"name":"Progesterone Lozenges","otherNames":[]},{"name":"Matched Placebo Lozenges","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"INCLUSION:\n\n1. Subject must be between the ages of 13 and 45.\n2. Subject must have a history of seizures (documented by EEG).\n3. Subject must have had at least 2 seizures or auras per month during the past 3 months.\n4. Subject must be on stable antiepileptic drug therapy for at least 2 months.\n5. Subject must have cycle intervals between 21 and 35 days during 6 months prior to entry.\n\nEXCLUSION:\n\n1. Subject that is pregnant or lactating.\n2. Subject that is on major tranquilizers, antidepressant medications, or reproductive hormones.\n3. Subject that is unable to document seizures.\n4. Subject that has progressive neurological or systemic disorder or \\> 2-fold elevation in liver enzyme levels","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"13 Years","maximumAge":"45 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency","description":"Percent of women who show a greater than 50% decline in average daily seizure frequency","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"20.2","spread":null},{"groupId":"OG003","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Women Who Show a >50% Decline in Average Daily Seizure Frequency for the Most Severe Seizure Type.","description":"Percent of women who show a \\>50% decline in average daily seizure frequency for the most severe seizure type.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":null},{"groupId":"OG001","value":"24.4","spread":null},{"groupId":"OG002","value":"22.2","spread":null},{"groupId":"OG003","value":"28.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency for Secondary Generalized, Complex Partial and Simple Partial Seizures Considered Separately","description":"Percentage of women who show a greater than 50% decline in average daily seizure frequency for secondary generalized, complex partial and simple partial seizures considered separately","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.39","spread":null},{"groupId":"OG001","value":"29.41","spread":null},{"groupId":"OG002","value":"21.21","spread":null},{"groupId":"OG003","value":"20.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.68","spread":null},{"groupId":"OG001","value":"18.60","spread":null},{"groupId":"OG002","value":"21.21","spread":null},{"groupId":"OG003","value":"13.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.12","spread":null},{"groupId":"OG001","value":"41.21","spread":null},{"groupId":"OG002","value":"42.22","spread":null},{"groupId":"OG003","value":"31.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Serum Progesterone Levels in Subjects at Baseline and After Treatment.","description":"Changes in serum progesterone levels in subjects at baseline and after treatment with progesterone or placebo.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"9.1","spread":null},{"groupId":"OG002","value":"10.8","spread":null},{"groupId":"OG003","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"9.2","spread":null},{"groupId":"OG002","value":"49.6","spread":null},{"groupId":"OG003","value":"12.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum Levels of Antiepileptic Drugs on Progesterone and Placebo for Subjects With Catamenial and Non-catamenial Epilepsy.","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"2.5"},{"groupId":"OG001","value":"9.6","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":"17.1"},{"groupId":"OG001","value":"22.6","spread":"12.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"8.2"},{"groupId":"OG001","value":"8.4","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"6.9"},{"groupId":"OG001","value":"9.3","spread":"4.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"6.5"},{"groupId":"OG001","value":"17.9","spread":"3.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":85},"commonTop":["Fatigue","Dizziness","Depression","Other","Diarrhea"]}}}